Drug Search Results
More Filters [+]

VGX-3400

Alternative Names: vgx-3400, vgx3400, vgx 3400, vgx-3400x
Latest Update: 2017-09-13
Latest Update Note: Clinical Trial Update

Product Description

DNA plasmids encoding the hemagglutinin (HA), neuraminidase (NA), and M2e-NP antigen of the H5N1 avian influenza virus (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01184976)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GeneOne Life Science
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VGX-3400

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Influenza, Human|Influenza in Birds

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FLU-001

P1

Completed

Influenza, Human

2012-04-01

FLU-001

P1

Completed

Influenza in Birds|Influenza, Human

2011-11-01

Recent News Events

Date

Type

Title